Compare CUZ & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUZ | SRRK |
|---|---|---|
| Founded | 1958 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | N/A | 2018 |
| Metric | CUZ | SRRK |
|---|---|---|
| Price | $24.80 | $45.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $31.55 | ★ $47.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | ★ 3.48 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $955,949,000.00 | N/A |
| Revenue This Year | $14.95 | N/A |
| Revenue Next Year | $2.68 | $20,271.77 |
| P/E Ratio | $71.11 | ★ N/A |
| Revenue Growth | ★ 15.46 | N/A |
| 52 Week Low | $24.07 | $22.71 |
| 52 Week High | $31.66 | $46.98 |
| Indicator | CUZ | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 69.88 |
| Support Level | $25.33 | $39.51 |
| Resistance Level | $25.82 | $43.94 |
| Average True Range (ATR) | 0.53 | 2.25 |
| MACD | 0.02 | 0.56 |
| Stochastic Oscillator | 2.13 | 91.11 |
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.